June 24, 2021
Latham & Watkins advised Novo Holdings
on co-leading a US$245 Million Series D funding round for Quanta Dialysis
Technologies, a medical technology leader delivering on its vision for more
flexible and accessible dialysis care.
The round was co-led by hedge fund Glenview
Capital, with support from a broad group of other top-tier investors, including
BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management
LLC., Puhua Capital, Segulah Medical and Ancora, alongside Orlando Health, an
integrated delivery network. Existing shareholders also participated in the
round, including Wellington Partners, btov, Seroba and The Grands.
The Latham team was led by London corporate
partner Robbie McLaren, with associate Samantha Peacock. Advice on life science matters by was provided by associates Frances Stocks Allen, Sara Patel, and Oscar Bjartell; and on employment matters by associates Adam Ray and Kendall Burnett.